MUCOSAL HUMAN IMMUNODEFICIENCY VIRUS VACCINE LATE PRE-CLINICAL EVALUATION

Grant number: 1136351 | Funding period: 2018 - 2019

Completed

Abstract

Despite many candidate vaccines entering clinical development for protection against HIV, none has yet been successful. This proposal centres on late preclinical development for a novel mucosal vaccine strategy for HIV, which combines a preclinically-proven approach to generating strong T cell immune responses, with an existing approach to generating broadly neutralising antibody responses to HIV. Proof of synergy between these approaches will lead directly to clinical development.

University of Melbourne Researchers